Primary biliary cholangitis (PBC) is a rare liver disease. It blocks and destroys bile ducts in the liver. Doctors used to call it “primary biliary cirrhosis.” “Biliary” means bile.

Updated results from the Phase III ELATIVE trial reveal Iqirvo (elafibranor) significantly reduced fatigue in patients with ...

Liver disease is on the rise in the United States. Women are at a higher risk of developing a certain type of liver disease called Primary Biliary Cholangitis, ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

MAIT cells are good fighters. Researchers have found that MAIT cells can respond very quickly to infections. Their speed ...

This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen 2 ...

"Our deep expertise in treating liver disease has delivered the first and only treatment for hepatitis delta and the first treatment for primary biliary cholangitis that has demonstrated ...

Updated GLISTEN trial results presented at EASL 2025 confirm that the IBAT inhibitor linerixibat significantly improved worst ...

IQIRVO ® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis MISSISSAUGA, ON, April 28, 2025 /CNW ...

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...